SCHEDULE: Panacea Venture Takes 19.9% Stake in CASI Pharma, Huang Joins Board

Panacea Venture Healthcare Fund II, L.P. and related entities, led by James Huang, disclosed a 19.9% beneficial ownership in CASI Pharmaceuticals, Inc., with Huang joining the Board of Directors.

Summary

• Panacea Venture Healthcare Fund II, L.P., along with its general partner Panacea Venture Healthcare Fund II GP Company, Ltd., its sole owner Panacea Innovation Limited, and James Huang, collectively reported beneficial ownership of CASI Pharmaceuticals, Inc. Ordinary Shares.
• James Huang, a citizen of China, is the Founding Managing Partner of Panacea Venture and will be appointed to the Board of Directors of CASI Pharmaceuticals, Inc., effective October 1, 2025.
• Panacea Venture Healthcare Fund II, L.P. purchased 3,550,000 Ordinary Shares for an aggregate consideration of approximately $6.7 million.
• James Huang also holds options to purchase 111,571 Ordinary Shares, received in connection with his previous service as a director of the Issuer.
• The total beneficial ownership for James Huang and the Panacea Venture entities is 3,661,571 Ordinary Shares, representing 19.9% of the outstanding shares.
• The Reporting Persons acquired these securities for investment purposes and intend to continuously review their investment in the Issuer.
• On September 26, 2025, Panacea Venture Healthcare Fund II, L.P. purchased 1,500,000 Ordinary Shares directly from the Issuer at a price of $1.5350 per Ordinary Share.

Sentiment

Score: 7

Explanation: The filing indicates a significant strategic investment and board representation by a major investor, which is generally viewed as a positive catalyst for potential strategic changes and value creation, though it introduces an element of uncertainty regarding future corporate direction.

Positives

• A significant investment from Panacea Venture Healthcare Fund II, L.P. and related entities demonstrates confidence in CASI Pharmaceuticals, Inc.
• The appointment of James Huang, a Founding Managing Partner of Panacea Venture, to the Board of Directors brings a new strategic perspective and potentially strong governance.
• The stated intent to review investments and potentially engage in strategic discussions could lead to initiatives aimed at enhancing shareholder value.

Negatives

• The filing does not explicitly state any negatives for the company, but the potential for significant corporate changes could introduce uncertainty for existing operations and management.

Risks

• Reporting Persons may acquire additional securities or sell all or a portion of their holdings, which could impact share price volatility.
• Potential for engagement in discussions with management, the Board, and securityholders that could lead to extraordinary corporate transactions, such as a merger, reorganization, or take-private transaction, potentially resulting in de-listing or de-registration of Ordinary Shares.
• Consideration of sales or acquisitions of assets or businesses, which could alter the company's strategic focus.
• Potential for changes to the capitalization or dividend policy of the Issuer.
• Possible changes in management or the composition of the Board, which could lead to operational disruptions or shifts in company direction.

Future Outlook

The Reporting Persons intend to continuously review their investment in CASI Pharmaceuticals, Inc. and may acquire additional securities, sell existing holdings, or engage in discussions with management and the Board. They may also consider or seek to cause the Issuer to explore extraordinary corporate transactions, including mergers, reorganizations, take-private transactions, asset sales, changes to capitalization or dividend policy, or changes in management or Board composition.

Management Comments

• Reporting Persons acquired the securities for investment purposes and intend to review their investments in the Issuer on a continuing basis.
• Reporting Persons may engage in discussions with management, the Board, and securityholders of the Issuer and other relevant parties or encourage, cause or seek to cause the Issuer or such persons to consider or explore extraordinary corporate transactions.

Industry Context

In the biotechnology and pharmaceutical industry, a significant stake acquisition by an investment fund, coupled with a board appointment, often signals an intent to actively influence corporate strategy. This can be a catalyst for strategic shifts, potentially leading to accelerated development, M&A activities, or a re-evaluation of the company's market position to unlock shareholder value.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Related Party Transactions

• James Huang received options to purchase 111,571 Ordinary Shares in connection with his previous service as a director of the Issuer.
• Panacea Venture Healthcare Fund II, L.P. purchased 1,500,000 Ordinary Shares directly from the Issuer on September 26, 2025.

Stakeholder Impact

• Shareholders: Potential for strategic changes and value creation, but also uncertainty regarding future corporate direction and potential extraordinary transactions.
• Management and Board: Increased oversight and potential for shifts in strategic priorities due to the influence of a significant new board member and shareholder.
• Employees: Potential for operational changes or restructuring depending on future strategic decisions.

Next Steps

• Reporting Persons will continue to review their investments in CASI Pharmaceuticals, Inc.
• Reporting Persons may acquire additional securities or sell existing holdings.
• Reporting Persons may engage in discussions with the Issuer's management, Board, and other securityholders.
• Reporting Persons may explore or encourage extraordinary corporate transactions, including mergers, reorganizations, or changes in corporate structure and management.

Key Dates

Recommendation

The filing details a significant beneficial ownership by Panacea Venture and James Huang, who is joining the board. This signals potential for strategic shifts, including extraordinary corporate transactions, which could unlock value but also introduce uncertainty. Investors should hold and monitor developments closely as the intentions of the new significant shareholder unfold.

Keywords

CASI Pharmaceuticals, Panacea Venture, James Huang, Schedule 13D, beneficial ownership, board appointment, pharmaceuticals, biotechnology, investment, corporate governance